Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Spritam

Levetiracetam

RLDNDA 207958 4 strengths Aprecia Pharms
Approved
Jul 31, 2015
Strengths
4
Listed patents
3

What does the FDA Orange Book show for Spritam?

Spritam contains Levetiracetam and is the new drug FDA Orange Book record for NDA 207958. The application has 4 presentations with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 207958

New drug application identity from the Orange Book snapshot.

Application holder
Aprecia Pharmaceuticals LLC

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
4

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription and Discontinued

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
3

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
001250MGTABLET, FOR SUSPENSIONORALPrescriptionNone posted
RLD
002500MGTABLET, FOR SUSPENSIONORALPrescriptionNone posted
RLDRS
003750MGTABLET, FOR SUSPENSIONORALDiscontinuedNone posted
RLD
0041GMTABLET, FOR SUSPENSIONORALDiscontinuedNone posted
RLD

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Aprecia Pharmaceuticals LLC

The Orange Book identifies this organization as the applicant responsible for NDA 207958.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

Status varies by presentation: 2 prescription and 2 on the Discontinued Drug Product List

Orange Book status is assigned at the product-presentation level, so one strength can remain listed as prescription or OTC while another appears on the discontinued list.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

3 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Mar 14, 2034. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

105 other ANDAs and 6 other NDAs found

65 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 207958 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Tablet, For Suspension · Oral

Levetiracetam

1 application
Product rows
4
Active applications
1
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-207958

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

4 approved presentations · NDA 207958
RLD
Strength
250MG
Dosage form
TABLET, FOR SUSPENSION
Route
ORAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    11 yr 2 mo ago

  2. Today

  3. Patent 11160786 expires

    Listed drug product patent expiration.

    in 7 yr 9 mo

  4. Patent 9339489 expires

    Listed drug product patent expiration.

    in 7 yr 9 mo

  5. Patent 9669009 expires

    Listed method-of-use patent (U-2021) expiration.

    in 7 yr 9 mo

  6. Patent 9669009 expires

    Listed method-of-use patent (U-2022) expiration.

    in 7 yr 9 mo

  7. Patent 9669009 expires

    Listed method-of-use patent (U-1850) expiration.

    in 7 yr 9 mo

Patent & exclusivity timeline

Protection horizon
2026202720282029203020312032203320342035TodayPatent 11160786: 2034-03-14Patent 11160786Patent 9339489: 2034-03-14Patent 9339489Patent 9669009: 2034-03-14Patent 9669009Patent 9669009: 2034-03-14Patent 9669009Patent 9669009: 2034-03-14Patent 9669009
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

LEVETIRACETAM

Strength

250MG

Dosage form

TABLET, FOR SUSPENSION

Route

ORAL

TE code

Not listed

Application

NDA 207958

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
11160786in 7 yr 9 mo
Product
9339489in 7 yr 9 mo
ProductU-1850
9669009in 7 yr 9 mo
U-2021
9669009in 7 yr 9 mo
U-2022
9669009in 7 yr 9 mo
U-1850

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Levetiracetam family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Spritam: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 207958 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo